10 February 2010
Eleanor Malone
eleanor.malone@informa.com
Higher sales of its top-selling multiple sclerosis drug Tysabri (natalizumab), the benefits of its deal with
Johnson & Johnson and reduced R&D and SG&A spending all helped improve
Elan's financial results in 2009. Revenues were up by 11% to $1.1 billion and net loss before tax significantly was...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
